1. Introduction {#sec1}
===============

Bladder cancer is the second most common genitourinary malignancy and the sixth most common cancer in the world \[[@B1]\]. In China, the incidence of bladder cancer continues to increase \[[@B2]\]. The incidence of bladder cancer also increases with age, and the peak is reached approximately at the age of 60 years; bladder cancer is three times more common in men than in women \[[@B3]\]. Among the newly diagnosed cases of transitional cell carcinomas, approximately 75% to 80% of these cases present superficial tumours; 50% to 70% of these superficial tumours relapse within five years; and roughly 10% to 20% progress to a more aggressive disease \[[@B4]\]. Bladder cancer is a multifactorial disease mediated by genetic abnormalities, environmental factors, and chronic irritation \[[@B5]\]. Although many individuals are exposed to these risk factors, only a fraction of exposed individuals develop bladder cancer in their lifetime, suggesting that genetic variations may participate in bladder carcinogenesis.

Thrombospondin-1 (TSP-1) is an adhesive glycoprotein with a size of 450 kD initially discovered in platelets, where TSP-1 is sequestered in a platelet *α*-granule \[[@B6]\]. TSP-1 has been implicated in regulating numerous biological activities, including cell adhesion, cell migration, proliferation, angiogenesis, inflammation, and wound healing \[[@B7]--[@B12]\]. TSP-1 also elicits different effects on tumour growth and progression depending on the tumour type, leading to cancer progression and inhibition in different instances \[[@B11]--[@B18]\]. In bladder cancer, low TSP-1 expression is significantly associated with an increased risk of disease recurrence and decreased overall survival \[[@B17], [@B18]\].

Genetic factors have a critical function in initiating cancer. Studies have been conducted to assess the association between polymorphisms in candidate genes and bladder cancer risk \[[@B19]\]. To date, genetic polymorphisms in *TSP-1* gene are possibly associated with coronary artery disease and myocardial infarction \[[@B20], [@B21]\]. The transcriptional initiation site of the *TSP-1* gene was identified by Laherty et al. \[[@B22]\]. *TSP-1*-1223 A/G polymorphism is located in the 5′ near-gene region of the *TSP-1* gene, which may influence the transcriptional activity of *TSP-1*. Furthermore, *TSP-1*-1223 A/G polymorphism may participate in the aetiology and development of bladder cancer.

In the present study, *TSP-1*-1223 A/G polymorphism (rs2169830) may be involved in the predisposition to develop bladder cancer. To validate this hypothesis, we genotyped the polymorphism and determined its association with the risk of bladder cancer in our ongoing, hospital-based, case-control study in a Chinese population.

2. Materials and Methods {#sec2}
========================

2.1. Ethics Statement {#sec2.1}
---------------------

The study was approved by the Institutional Review Board of the First Affiliated Hospital of Nanjing Medical University, Nanjing, China. During recruitment, written informed consent was obtained from all of the participants involved in this study.

2.2. Patients and Controls {#sec2.2}
--------------------------

The present study included 609 patients with bladder cancer and 670 age-matched control subjects from Han population living in Jiangsu and Anhui provinces in Eastern China. The patients with bladder cancer were recruited from July 2006 to July 2012 in the Department of Urology, the First Affiliated Hospital of Nanjing Medical University. The patients were excluded in this study according to the following: previous cancer, metastasised cancer from other or unknown origins, and previously subjected to radiotherapy or chemotherapy. Diagnosis of bladder cancer was confirmed by histopathological analysis. Cancer-free control individuals were frequency matched with the cancer patients in terms of age (±5 years) and gender. We also ensured that these control subjects were genetically unrelated to the cases. All of the control subjects were recruited from healthy individuals who were scheduled for a physical examination in the outpatient department at the same hospital. The control subjects were excluded if they manifested symptoms of bladder cancer, such as haematuria. Prior to recruitment, all of the subjects were personally interviewed to collect demographic data and clinical characteristics, including age, gender, race, tobacco use, alcohol use, and self-reported family history of cancer. According to the tumour, node, and metastasis classification of cancer stages (2002 International Union Against Cancer), the clinical stage at the time of diagnosis was classified into two subgroups: nonmuscle invasive group (pTa-pT1) and muscle invasive group (pT2-pT4). According to histopathological grade (WHO 1973, grading of urothelial papilloma), the patients were classified into three subgroups: grades 1, 2, and 3. Individuals who smoked daily for \>1 year were defined as smokers and the rest were considered as nonsmokers. Individuals who drank alcohol at least three times per week for more than 6 months were defined as drinkers and the rest were considered as nondrinkers.

For survival analysis, 260 patients were followed up. Among these follow-up cases, 24 (24/260, 9.2%) were excluded because of incomplete follow-up data. Survival time was calculated from the date of confirmed diagnosis until the date of the last follow-up or recurrence. The date of recurrence was obtained from inpatient and outpatient records or from patients\' families via follow-up telephone calls. The patients who did not suffer from recurrence on the last follow-up date were considered as non-recurrent.

2.3. DNA Extraction and Polymorphism Genotyping {#sec2.3}
-----------------------------------------------

Genomic DNA of each individual was extracted from 150 *μ*L of EDTA-anticoagulated peripheral blood samples by using a DNA extraction kit (Tiangen Biotech, Beijing, China) according to the manufacturer\'s instructions. The *TSP-1*-1223 A/G polymorphism was genotyped using TaqMan single nucleotide polymorphism (SNP) genotyping assay (Applied Biosystems, Foster City, CA, USA). SDS 2.4 software was used for allelic discrimination. The primers, probes, and reaction conditions of each SNP are available upon request. For quality control, four negative controls were included in each plate, and 5% of the samples were randomly selected for repeated genotyping to verify the results; all of the results were 100% consistent.

2.4. Quantitative Real-Time PCR {#sec2.4}
-------------------------------

Total RNA from 66 bladder cancer tissues was extracted using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer\'s protocol. Total RNA (1 *μ*g) was used for cDNA synthesis with oligo-dT primers (Invitrogen, Karlsruhe, Germany) and superscript II reverse transcriptase (Takara Bio, Shiga, Japan). PCR was performed using PCR Master (Roche, Mannheim, Germany) with the following primers: for *TSP-1* mRNA, 5′-ACTGTCCATTCCATTACAACCCAGC-3′ (forward) and 5′-TGTCACACTGATCTCCAACCCCATCCA-3′ (reverse); and for **β*-actin*, 5′-ACTGGAACGGTGAAGGTGAC-3′ (forward) and 5′-AGAGAAGTGGGGTGGCTTTT-3′ (reverse). Fold changes were normalised based on **β*-actin* expression, and each assay was conducted in a 384-well ABI 7900HT real-time PCR system (Applied Biosystems, Foster City, CA, USA). This procedure was performed in triplicate.

2.5. Statistics Analysis {#sec2.5}
------------------------

The frequency distributions of the selected demographic variables as well as each allele and genotype of the *TSP-1*-1223 A/G polymorphism between the cases and the control subjects were evaluated using *χ* ^2^-type distribution. Hardy-Weinberg equilibrium (HWE) was determined using a goodness-of-fit *χ* ^2^ test. Unconditional univariate and multivariate logistic regression analyses were conducted to calculate the crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) to determine the risk of bladder cancer. Interaction was investigated using a multiplicative interaction term included in the multivariate model. To investigate potential interactions between the polymorphism and tobacco smoking, we assessed a multiplicative gene-environment interaction by logistic regression analysis, including the main effect variables and their product terms. Hazard ratios (HRs) and 95% CIs of the HRs were derived from univariate and multivariate Cox proportional hazard models. Survival curves were generated using the Kaplan-Meier method and compared using the log-rank-Mantel-Cox test. All of the analyses were carried out using SPSS 13.0. A two-sided *P* value \<0.05 represented a statistically significant result.

3. Results {#sec3}
==========

3.1. Characteristics of the Study Population {#sec3.1}
--------------------------------------------

The frequency distributions of the selected characteristics of the cases and the control subjects are shown in [Table 1](#tab1){ref-type="table"}. The cases and the control subjects were adequately matched in terms of age and gender (*P* = 0.486 for age and *P* = 0.091 for gender). A higher number of smokers were found among the cases than the control subjects (47.9% versus 36.4%; *P* \< 0.001). No significant difference in drinking status was found between the cases and the control subjects (*P* = 0.196). In addition, the frequency of the first-degree relatives with cancer was higher in the cases than in the control subjects (27.8% versus 7.2%; *P* \< 0.001). These variables were further adjusted in the multivariate logistic regression analysis to assess the main effect of the *TSP-1*-1223 A/G polymorphism on bladder cancer risk. The clinicopathological characteristics of 609 cases with bladder cancer are listed in [Table 1](#tab1){ref-type="table"}.

3.2. Association between *TSP-1*-1223 A/G Polymorphism and Risk of Bladder Cancer {#sec3.2}
---------------------------------------------------------------------------------

The genotype and allele frequency distributions of the *TSP-1*-1223 A/G polymorphism among the cases and the control subjects as well as their associations with the risk of bladder cancer are presented in [Table 2](#tab2){ref-type="table"}. The genotype frequencies in the control subjects are consistent with those of HWE (*P* = 0.851). The frequencies of AA, AG, and GG genotypes were 47.1%, 40.2%, and 12.6% among the cases and 43.9%, 44.5%, and 11.6% among the control subjects, respectively (*P* = 0.307). No correlation was observed between *TSP-1*-1223 A/G polymorphism and the risk of bladder cancer. We further assessed the effect of *TSP-1*-1223 A/G polymorphism on the risk of bladder cancer risk stratified by age, gender, smoking status, drinking status, self-reported family history of cancer, and tumour grade and tumour stage (Tables [3](#tab3){ref-type="table"}, [4](#tab4){ref-type="table"}, and [5](#tab5){ref-type="table"}). Logistic regression analysis also showed no association between *TSP-1*-1223 A/G polymorphism and bladder cancer risk.

3.3. Interaction between *TSP-1*-1223 A/G Polymorphism and Tobacco Smoking {#sec3.3}
--------------------------------------------------------------------------

A significantly increased risk was observed in smokers with AA/AG genotypes compared with nonsmokers exhibiting AA/AG genotypes (*P* = 0.001; ORs = 1.58; 95% CI = 1.20 to 2.10; [Table 6](#tab6){ref-type="table"}). We then evaluated whether or not an interaction between smoking status and *TSP-1*-1223 A/G polymorphism status occurs. We did not observe a multiplicative interaction effect between polymorphism and smoking status (*P* = 0.823; [Table 6](#tab6){ref-type="table"}).

3.4. Effects of *TSP-1*-1223 A/G Polymorphism and Bladder Cancer Recurrence {#sec3.4}
---------------------------------------------------------------------------

We further investigated whether or not *TSP-1*-1223 A/G polymorphism is associated with the recurrence of bladder cancer. The demographic and clinical characteristics at primary diagnosis and the genotype distribution in patients with bladder cancer are shown in [Table 7](#tab7){ref-type="table"}. The median follow-up duration for the 236 patients was 19 months (range, 1 month to 68 months). The mean time-to-recurrence was 20.8 months (95% CI = 17.2 to 24.3 months). Kaplan-Meier curves showed statistical difference between *TSP-1*-1223 A/G polymorphism and time-to-recurrence in bladder cancer (AA 20.5 months, 95% CI = 14.7 to 26.3; AG 22.2 months, 95% CI 15.6 to 28.7; GG 18.8 months, 95% CI 12.7--25.0; log-rank test, *P* = 0.017, [Figure 2](#fig2){ref-type="fig"}). Compared with AA + AG genotypes, the GG genotype exhibited a significant recurrence risk of bladder cancer (HR = 2.07, 95% CI = 1.23 to 3.49, *P* = 0.006), and the recurrence risk was more prominent among patients with the GG genotype (HR = 2.63, 95% CI = 1.43 to 4.83, *P* = 0.002). The cases exhibiting AG + GG genotypes were also associated with an increased recurrence risk compared with the AA genotype (HR = 1.95, 95% CI = 1.20 to 3.19, *P* = 0.007; [Table 8](#tab8){ref-type="table"}).

3.5. Association between *TSP-1*-1223 A/G Polymorphism and *TSP-1* mRNA Expression {#sec3.5}
----------------------------------------------------------------------------------

To evaluate the association between *TSP-1*-1223 A/G polymorphism and recurrence of bladder cancer, we examined whether or not the *TSP-1*-1223 A/G polymorphism was associated with an altered *TSP-1* mRNA expression. No significant difference was observed in the relative *TSP-1* mRNA expression level between patients with AA (*n* = 23) and AG (*n* = 28) genotypes (*P* = 0.103). The patients with the GG genotype exhibited lower *TSP-1* mRNA expression levels than those with AA genotype (*n* = 15; *P* = 0.002), although a significant overlap among the three groups was observed ([Figure 1](#fig1){ref-type="fig"}).

4. Discussion {#sec4}
=============

In the present study, the association between -1223 A/G polymorphism in *TSP-1* gene (rs2169830) and risk of bladder cancer was investigated. The results do not indicate that the genotypes of the *TSP-1*-1223 A/G polymorphism are associated with an increased bladder cancer incidence. However, the time-to-recurrence was significantly shorter in G allele carriers than that in individuals with a homozygous AA genotype. Patients with the AG/GG genotypes have 1.95 times greater risk of the recurrence of bladder cancer than those with the AA genotype (*P* = 0.007). Furthermore, individuals with the GG genotype exhibited a higher risk of recurrence than those with the AA genotype (OR = 2.63, *P* = 0.002). To the best of our knowledge, this study is the first to investigate the function of the *TSP-1*-1223 A/G polymorphism in the aetiology of bladder cancer.

TSP-1 has been implicated in tumour growth and progression by regulating cell adhesion \[[@B23]\], motility \[[@B24]\], proliferation \[[@B25]\], and angiogenesis \[[@B26]\]. As a multifunctional protein involved in tumour growth regulation, TSP-1 elicits an inhibitory effect on the growth of various malignancies such as melanoma \[[@B27]\], prostate cancer \[[@B28]\], cutaneous squamous cell carcinoma \[[@B29]\], and glioblastoma \[[@B30]\]. Strong evidence has also suggested that TSP-1 may stimulate lung cancer \[[@B31]\] and breast cancer \[[@B32]\].

A previous study identified that TSP-1, secreted by normal urothelium cells, is responsible for antiangiogenic activity \[[@B33]\]. Angiogenesis is associated with an increased recurrence risk of bladder cancer \[[@B34]\]. The downregulation of TSP-1 in bladder cancer is considered as a primary factor contributing to specific changes, for instance, from an antiangiogenic to an angiogenic phenotype during cancer development and recurrence \[[@B17], [@B18], [@B33]\].

Most of the *TSP-1* SNPs have only been observed in cardiac disease \[[@B20], [@B21]\]; no studies have been shown to provide a relationship between *TSP-1* gene polymorphism and cancer. In our study, the GG/AG genotypes of the *TSP-1*-1223 A/G polymorphism in bladder cancer were associated with a shorter time-to-recurrence than the AA genotype. Individuals carrying the lower production genotype of *TSP-1*-1223 A/G polymorphism possibly possess an enhanced ability to promote the recurrence of bladder cancer.

Using the program TFSEARCH, we found that the G allele of *TSP-1*-1223 A/G polymorphism was located in the consensus DNA sequence TGTGGT. The DNA sequence was a potential transcription regulation region, which can be recognised by AML1-a \[[@B35], [@B36]\]. However, any transcriptional factor was not bound to the sequence TGTGAT containing the A allele of the *TSP-1*-1223 A/G polymorphism. Furthermore, AML1-a participates as a transcription inhibitor by suppressing the transcriptional activation of AML1-b \[[@B37]\]. Thus, we cautiously speculated that AML1-a binds to the consensus sequence (TGTGGT) of the G allele in the *TSP-1*-1223 A/G polymorphism, thereby suppressing the transcription of *TSP-1*.

A previous study revealed that TSP-1 can suppress VEGF mobilisation from the extracellular matrix by inhibiting the activity of MMP-9 \[[@B38]\]. TSP-1 can also inhibit the activity of VEGF by interacting directly with VEGF \[[@B39]\]. The possible mechanism between angiogenesis and bladder cancer recurrence has been related to an increased VEGF expression level, which serves as a major factor in angiogenesis \[[@B40]\]. The increased expression level of VEGF was implicated in the pathogenesis of bladder cancer recurrence by promoting the growth and implantation of a bladder cancer cell via angiogenesis \[[@B41]\]. Conversely, decreased TSP-1 may be associated with an increased risk of bladder cancer recurrence via the inhibitory effect of TSP-1 on VEGF-mediated tumour angiogenesis.

In the current study, the expression level of *TSP-1* mRNA in bladder cancer samples was lower in patients with heterozygous G allele than those with homozygous A allele. The expression level of *TSP-1* mRNA was the lowest in individuals with homozygous G allele. As such, the shorter time-to-recurrence in patients with bladder cancer exhibiting a G allele may be attributed to a decreased *TSP-1* expression, which has been associated with an increased risk of disease recurrence and a decreased overall survival by promoting tumour neovascularization \[[@B17], [@B18], [@B34]\]. Our results partly supported our hypothesis; however, further functional experiments should be conducted to validate the specific mechanism.

Several potential limitations are observed in the present study. First, our sample size was relatively small, which may limit the statistical power of our study, particularly for gene-environment interaction analyses. Second, our study was a hospital-based case-control study; hence, we cannot rule out the possibility of selection bias for subjects who may have been associated with a particular genotype.

In conclusion, our study shows that G allele in *TSP-1*-1223 A/G polymorphism may modulate the risk of recurrence in bladder cancer. A lack of association between *TSP-1*-1223 A/G polymorphism and risk of bladder cancer was observed in our population. Nevertheless, a possible function of this polymorphism in other cancers or in other bladder cancer populations should be considered. Hence, additional studies should be conducted to confirm the specific function of *TSP-1*-1223 A/G polymorphism in bladder cancer development.
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###### 

Frequency distribution of selected variables of the bladder cancer cases and controls.

  Variables                  Cases (*n* = 609)   Controls (*n* = 670)   *P* ^a^          
  -------------------------- ------------------- ---------------------- --------- ------ ---------
  Age (year)                                                                              
   \<65                      289                 47.5                   331       49.4   0.486
   ≥65                       320                 52.5                   339       50.6    
  Sex                                                                                     
   Male                      484                 79.5                   506       75.5   0.091
   Female                    125                 20.5                   164       24.5    
  Smoking status                                                                          
   Never                     317                 52.1                   426       63.6   \<0.001
   Ever                      292                 47.9                   244       36.4    
  Drinking status                                                                         
   No                        418                 68.6                   482       71.9   0.196
   Yes                       191                 31.4                   188       28.1    
  Family history of cancer                                                                
   No                        440                 72.2                   622       92.8   \<0.001
   Yes                       169                 27.8                   48        7.2     
  Tumor stage                                                                             
   Nonmuscle invasive        466                 76.5                                     
   Muscle invasive           143                 23.5                                     
  Tumor grade                                                                             
   Grade 1                   298                 48.9                                     
   Grade 2                   194                 31.9                                     
   Grade 3                   117                 19.2                                     

^a^Student\'s *t*-test for age distribution between the cases and controls; two-sided *χ* ^2^ test for other selected variables between the cases and controls.

###### 

Genotype and allele frequencies of the *TSP-1*-1223 A/G polymorphism among the bladder cancer cases and controls.

  Genotypes   Cases (*n* = 609)   Controls (*n* = 670)   *P* ^a^   Crude OR (95% CI)   *P* ^b^   Adjusted OR (95% CI)^b^           
  ----------- ------------------- ---------------------- --------- ------------------- --------- ------------------------- ------- -------------------
  AA          287                 47.1                   294       43.9                          1.00 (reference)                  1.00 (reference)
  AG          245                 40.2                   298       44.5                0.151     0.84 (0.66--1.07)         0.083   0.80 (0.62--1.03)
  GG          77                  12.6                   78        11.6                0.951     1.01 (0.70--1.46)         0.603   1.11 (0.75--1.63)
                                                                                                                                   
  AA          287                 47.1                   294       43.9                          1.00 (reference)                  1.00 (reference)
  AG + GG     322                 52.9                   376       56.1                0.244     0.88 (0.70--1.10)         0.191   0.85 (0.67--1.08)
                                                                                                                                   
  AG + AA     532                 87.4                   592       86.6                          1.00 (reference)                  1.00 (reference)
  GG          77                  12.6                   78        13.4                0.583     1.10 (0.77--1.56)         0.330   1.20 (0.83--1.72)
                                                                                                                                   
  A allele    819                 67.2                   886       66.1                                                             
  G allele    399                 32.8                   454       33.9                0.548                                        

CI: confidence interval; OR: odds ratio.

^a^Two-sided *χ* ^2^ test for either genotype distributions or allele frequencies between the cases and controls.

^b^Adjusted for age, gender, smoking, drinking status, and family history of cancer in logistic regression model.

###### 

Stratification analyses between *TSP-1*-1223 A/G polymorphism and risk of bladder cancer.

  Variables                            Genotypes (cases/controls)                                                                       
  -------------------------- --------- ---------------------------- ----------- ------- ----------- ------- ------------------- ------- -------------------
  *Total*                                                                                                                                
  Age (year)                                                                                                                             
   \<65                      289/331   243/289                      84.1/87.3   46/42   15.9/12.7   0.251   1.30 (0.81--2.10)   0.128   1.38 (0.86--2.25)
   ≥65                       320/339   289/303                      90.3/89.4   31/36   9.7/10.6    0.692   0.90 (0.53--1.55)   0.719   0.94 (0.55--1.61)
  Sex                                                                                                                                    
   Male                      484/506   423/457                      87.4/90.3   61/49   12.6/9.7    0.144   1.34 (0.89--2.05)   0.127   1.39 (0.91--2.13)
   Female                    125/164   109/135                      87.2/82.3   16/29   12.8/17.7   0.257   0.68 (0.33--1.38)   0.495   0.78 (0.38--1.60)
  Smoking status                                                                                                                         
   Never                     317/426   278/377                      87.7/88.5   39/49   12.3/11.5   0.738   1.08 (0.67--1.73)   0.381   1.25 (0.76--2.05)
   Ever                      292/244   254/215                      86.6/88.1   38/29   13.4/11.9   0.694   1.11 (0.64--1.93)   0.747   1.10 (0.63--1.91)
  Drinking status                                                                                                                        
   No                        418/482   367/423                      87.8/87.8   51/59   12.2/12.2   0.986   1.00 (0.65--1.52)   0.644   1.11 (0.71--1.73)
   Yes                       191/188   165/169                      86.4/89.9   26/19   13.6/10.1   0.291   1.40 (0.71--2.79)   0.396   1.34 (0.68--2.64)
  Family history of cancer                                                                                                               
   No                        440/622   385/547                      87.5/87.9   55/75   12.5/12.1   0.829   1.04 (0.70--1.53)   0.558   1.12 (0.76--1.65)
   Yes                       169/48    147/45                       87.0/93.7   22/3    13.0/6.3    0.195   2.24 (0.63--12.2)   0.284   2.02 (0.56--7.26)

CI: confidence interval; OR: odds ratio.

^a^Two-sided *χ* ^2^ test for either genotype distributions or allele frequencies between the cases and controls.

^b^Adjusted for age, gender, smoking, drinking status, and family history of cancer in logistic regression model.

###### 

The associations between *TSP-1*-1223 A/G polymorphism and the development of bladder cancer.

  Variables              Genotypes   *P* ^a^   Crude OR (95% CI)   *P* ^b^   Adjusted OR (95% CI)^b^                               
  ---------------------- ----------- --------- ------------------- --------- ------------------------- ------------------- ------- -------------------
  Controls (*n* = 670)   592         88.4      78                  11.6                                1.00 (reference)            1.00 (reference)
  Cases (*n* = 609)                                                                                                                 
  Tumor stage                                                                                                                       
   Nonmuscle invasive    407         87.3      59                  12.7      0.604                     1.10 (0.75--1.60)   0.341   1.21 (0.82--1.79)
   Muscle invasive       125         87.4      18                  12.6      0.750                     1.09 (0.59--1.92)   0.488   1.23 (0.68--2.22)
  Tumor grade                                                                                                                       
   Grade 1               264         88.6      34                  11.4      0.917                     0.98 (0.62--1.52)   0.842   1.05 (0.67--1.65)
   Grade 2               168         86.6      26                  13.4      0.507                     1.17 (0.70--1.92)   0.271   1.35 (0.79--2.30)
   Grade 3               100         85.5      17                  14.5      0.376                     1.29 (0.69--2.31)   0.158   1.58 (0.84--2.97)
  Number                                                                                                                            
   Single                384         88.1      52                  11.9      0.886                     1.03 (0.69--1.52)   0.550   1.13 (0.76--1.69)
   Multiple              148         85.5      25                  14.5      0.315                     1.28 (0.75--2.12)   0.160   1.47 (0.86--2.50)
  Size                                                                                                                              
   \<3 cm                345         88.2      46                  11.8      0.952                     1.01 (0.67--1.51)   0.800   1.06 (0.70--1.60)
   ≥3 cm                 187         85.8      31                  14.2      0.314                     1.26 (0.78--2.00)   0.074   1.56 (0.96--2.55)

CI: confidence interval; OR: odds ratio.

^a^Two-sided *χ* ^2^ test for either genotype distributions or allele frequencies between the cases and controls.

^b^Adjusted for age, gender, smoking, drinking status, and family history of cancer in logistic regression model.

###### 

*TSP-1*-1223 A/G polymorphism and clinicopathological characteristics in patients with bladder cancer.

  Clinicopathological characteristics   Genotypes *n* (%)   *P* ^a^     Adjusted OR (95% CI)^a^   
  ------------------------------------- ------------------- ----------- ------------------------- -------------------
  Tumor stage                                                                                      
   Nonmuscle invasive                   407 (87.3)          59 (12.7)                             1.00 (reference)
   Muscle invasive                      125 (87.4)          18 (12.6)   0.979                     1.01 (0.57--1.78)
  Tumor grade                                                                                      
   Grade 1                              264 (88.6)          34 (11.4)                             1.00 (reference)
   Grade 2                              168 (86.6)          26 (13.4)   0.440                     1.26 (0.71--2.23)
   Grade 3                              100 (85.5)          17 (14.5)   0.294                     1.43 (0.73--2.79)
  Number                                                                                           
   Single                               384 (88.1)          52 (11.9)                             1.00 (reference)
   Multiple                             148 (85.5)          25 (14.5)   0.433                     1.23 (0.73--2.07)
  Size                                                                                             
   \<3 cm                               345 (88.2)          46 (11.8)                             1.00 (reference)
   ≥3 cm                                187 (85.8)          31 (14.2)   0.367                     1.24 (0.74--2.08)

CI: confidence interval; OR: odds ratio.

^a^Adjusted for age, gender, smoking, drinking status, and family history of cancer in logistic regression model.

###### 

Interaction analyses of the *TSP-1*-1223 A/G polymorphism and tobacco smoking.

  Smoking status                       Genotypes   Cases   Controls   *P* ^a^   Crude OR (95% CI)^a^   *P* ^b^   Adjusted OR (95% CI)^b^           
  ------------------------------------ ----------- ------- ---------- --------- ---------------------- --------- ------------------------- ------- -------------------
  Nonsmokers                           AA + AG     278     45.7       377       56.3                             1.00 (reference)                  1.00 (reference)
  Nonsmokers                           GG          39      6.4        49        7.3                    0.738     1.08 (0.67--1.73)         0.381   1.25 (0.76--2.05)
  Smokers                              AA + AG     254     41.7       215       32.1                   \<0.001   1.60 (1.25--2.05)         0.001   1.58 (1.20--2.10)
  Smokers                              GG          38      6.2        29        4.3                    0.025     1.78 (1.04--3.06)         0.158   1.52 (0.85--2.73)
  *P* ~Interaction~ (multiplicative)                                  0.823                                                                        

CI: confidence interval; OR: odds ratio.

^a^Two-sided *χ* ^2^ test for either genotype distributions or allele frequencies between the cases and controls.

^b^Adjusted for age, gender, smoking, drinking status, and family history of cancer in logistic regression model.

###### 

Demographic and clinical characteristics at primary diagnosis and genotype distribution in patients with bladder cancer.

                                  All              Genotypes        *P*                               
  ------------------------------- ---------------- ---------------- ---------------- ---------------- -------
  *N* (%)                         236              104 (44.1)       91 (38.6)        41 (17.4)         
  Sex (M/F)                       190/46           87/17            73/18            30/11            0.356
  Mean age at diagnosis (years)   63.79 (±12.78)   63.63 (±13.44)   63.78 (±12.02)   64.22 (±13.02)   0.969
  Tumor stage                                                                                          
   Nonmuscle invasive             184 (80.0)       84 (45.7)        69 (37.5)        31 (16.8)         
   Muscle invasive                52 (20.0)        20 (38.5)        22 (42.3)        10 (19.2)        0.653
  Tumor grade                                                                                          
   Grade 1                        120 (50.8)       52 (43.3)        51 (42.5)        17 (14.2)         
   Grade 2                        78 (33.1)        39 (50.0)        24 (30.8)        15 (19.2)         
   Grade 3                        38 (16.1)        13 (34.2)        16 (42.1)        9 (23.7)         0.283
  Number                                                                                               
   Single                         168 (71.2)       77 (45.8)        64 (38.1)        27 (16.1)         
   Multiple                       68 (28.8)        27 (39.7)        27 (39.7)        14 (20.6)        0.602
  Size                                                                                                 
   \<3 cm                         118 (75.9)       56 (47.5)        42 (35.6)        20 (16.9)         
   ≥3 cm                          118 (24.1)       48 (40.7)        49 (44.4)        21 (14.8)        0.555

###### 

Genotype and allele frequencies of the *TSP-1*-1223 A/G polymorphism among the bladder cancer cases with survival information.

  Genotypes   Recurrence (*n* = 78)   Nonrecurrence (*n* = 158)   *P* ^b^   Adjusted HR (95% CI)^b^               
  ----------- ----------------------- --------------------------- --------- ------------------------- ----------- -----------------------
  AA          25                      32.1                        79        50.0                                  1.00 (reference)
  AG          33                      42.3                        58        36.7                      0.062       1.68 (0.97--2.88)
  GG          20                      25.6                        21        13.3                      **0.002**   **2.63 (1.43--4.83)**
                                                                                                                  
  AA          25                      32.1                        79        50.0                                  1.00 (reference)
  AG + GG     53                      67.9                        79        50.0                      **0.007**   **1.95 (1.20--3.19)**
                                                                                                                  
  AG + AA     58                      74.4                        137       86.7                                  1.00 (reference)
  GG          20                      25.6                        21        13.3                      **0.006**   **2.07 (1.23--3.49)**
                                                                                                                  
  A allele    83                      53.2                        216       63.4                                   
  G allele    73                      46.8                        100       36.6                                  *P* ^a^ = 0.001

CI: confidence interval; HR: hazard ratio.

^a^Two-sided *χ* ^2^ test for allele frequencies between the cases and controls.

^b^Adjusted for age, gender, smoking, drinking status, and family history of cancer in cox regression model.

The bold font refers to the statistical significance of result.

[^1]: Academic Editor: Brian Wigdahl
